After a solid multi year run, Neurocrine Biosciences stock now screens as roughly fairly valued on market multiples, and the broader valuation checks point to a more balanced picture than a clear bargain or an obvious stretch.
- Neurocrine Biosciences has returned 73.4% over the past 5 years, which puts recent gains at the center of any valuation discussion today.
- Expectations around the durability of its cash generation from existing treatments can support the current price. Any setback in execution or pressure on profitability, however, may weigh on what investors are willing to pay.
- The stock earns a mixed value profile, with 3 out of 6 valuation checks suggesting it is on the expensive side and the rest looking more reasonable.
The issue now is whether Neurocrine Biosciences' recent performance justifies the present valuation or leaves limited room for missteps.
Find out why Neurocrine Biosciences' 29.4% return over the last year is lagging behind its peers.
Does Neurocrine Biosciences Look Fairly Valued on Earnings?
The P/E ratio is a useful way to think about Neurocrine Biosciences because earnings are a key driver of how investors currently value the stock. The shares trade on a P/E of 25.7x, which is above the broader Biotechs industry average of 17.3x and slightly higher than the peer group at 23.4x. That points to investors paying a premium for each dollar of Neurocrine Biosciences' earnings compared with many sector peers.
A more tailored benchmark that weighs factors like the company's growth profile, profitability, size and risk suggests a fair P/E of 26.0x. The current 25.7x multiple sits very close to this mark, indicating that, on this framework, Neurocrine Biosciences does not screen as especially cheap or especially expensive. For you as a shareholder or potential investor, this means the P/E already reflects a balanced set of expectations around its earnings power.
Overall, Neurocrine Biosciences appears roughly fairly valued on its P/E multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Neurocrine Biosciences Narrative: What Would Justify Today's Price?
For Neurocrine Biosciences, Simply Wall St Narratives sit between the current P/E-based valuation puzzle and clear, testable views on what could make the stock worth materially more or less than today’s price, by spelling out which paths for growth, margins and earnings would need to play out. Each narrative links its number to a specific view on where growth, profitability and risks might head next, giving you a reference point to revisit as new information emerges.
The community is split on Neurocrine Biosciences, with one camp focused on product breadth and another fixated on concentration and policy risk.
Bull case: 30% undervalued
"Neurocrine Biosciences is diversifying its revenue streams, with a robust late-stage pipeline and early commercial traction from CRENESSITY adding to its established blockbuster INGREZZA, which could support significant future revenue and earnings growth if these new assets perform well…"
Read the full Bull Case to see why Neurocrine Biosciences could be undervalued
Bear case: 13% overvalued
"Heavy dependence on INGREZZA and CRENESSITY exposes the company to regulatory, reimbursement, and competition risks that could threaten revenue growth and margins…"
Read the full Bear Case to see why Neurocrine Biosciences could be overvalued
Do you think there's more to the story for Neurocrine Biosciences? Head over to our Community to see what others are saying!
The Bottom Line
For now, Neurocrine Biosciences looks roughly in line with what the market is willing to pay for its earnings, with neither a clear discount nor a clear premium on the overall checks. That puts the focus squarely on whether the company can keep translating its current product set into resilient cash generation without meaningful hits to margins or pricing. The crux for both bulls and bears is how durable earnings from core treatments prove to be, and whether that is enough to defend the existing P/E multiple if sentiment around concentration or policy risk shifts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com